Specific metabolic impairments indicate loss of sustained liver improvements in metabolic dysfunction-associated steatotic liver disease treatment.

Ling LuoJunzhao YeShuyu ZhuoBo MaWeiyi MaiXiaopei CaoLiuqin LiangWei WangShiting FengZhi DongBihui Zhong

Published in: Hepatobiliary surgery and nutrition (2024)

MASLD patients with IR and high TBA levels are at higher risks of subsequent diminished sustained improvements of steatosis and fibrosis, respectively.

Keyphrases

insulin resistance
oxidative stress
type diabetes
human health
risk assessment
metabolic syndrome
adipose tissue
skeletal muscle
liver fibrosis